The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody
Open accessAbstract
Castleman's disease (angiofollicular lymphoid hyperplasia) is a heterogeneous group of lymphoproliferative disorders of uncertain cause1. Two pathologic types, hyaline vascular and plasma-cell disease, have been recognized. The plasma-cell variant of Castleman's disease may be localized or multicentric. Multicentric disease is a systemic lymphoproliferative disorder characterized by lymphadenopathy, hepatosplenomegaly, and constitutional symptoms. Anemia, hypoalbuminemia, and hypergammaglobulinemia are also common. Interleukin-6, a cytokine with pleiotropic effects on the immune system, hematopoiesis, and acute-phase reactions, is a putative growth factor in multiple myeloma and may also be central to the pathophysiology of Castleman's disease2–7. Administration of a murine anti-interleukin-6 monoclonal . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Localized mediastinal lymph-node hyperplasia resembling thymoma
Castleman, B., Iverson, L., & Menendez, V. P. (1956) · Cancer · doi:10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4 · Cited by 1,621
Keller, A. R., Hochholzer, L., & Castleman, B. (1972) · Cancer · doi:10.1002/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-# · Cited by 1,355
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
Klein, B., Zhang, X., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., & Bataille, R. (1989) · Blood · doi:10.1182/blood.v73.2.517.517 · Cited by 763
Self-citationHsu, S. M., & Soban, E. (1982) · Journal of Histochemistry & Cytochemistry · doi:10.1177/30.10.6182185 · Cited by 659
Self-citationSERUM LEVELS OF INTERLEUKIN-6 AND ACUTE PHASE RESPONSES
Nijsten, M. W. N., De Groot, E. R., Ten Duis, H. J., Klasen, H. J., Hack, C. E., & Aarden, L. A. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91413-9 · Cited by 458
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 418
Self-citationHuman interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro.
Ishibashi, T., Kimura, H., Uchida, T., Kariyone, S., Friese, P., & Burstein, S. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5953 · Cited by 407
Cited by
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
Lucey, D. R., Clerici, M., & Shearer, G. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.532 · Cited by 666
Clinical implications of dysregulated cytokine production
Slifka, M. K., & Whitton, J. L. (2000) · Journal of Molecular Medicine · doi:10.1007/s001090000086 · Cited by 655
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Metadata
- Authors
- Beck, J. T., Hsu, S.-M., Wijdenes, J., Bataille, R., Klein, B., Vesole, D., Hayden, K., Jagannath, S., & Barlogie, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-03-03
- Volume
- 330
- Issue
- 9
- Pages
- 602-605
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2328705550
- Cited by
- 322
- References
- 13
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody. https://app.cochat.ai/papers/10.1056/nejm199403033300904
- The paper
- Beck, J. T., Hsu, S.-M., Wijdenes, J., Bataille, R., Klein, B., Vesole, D., Hayden, K., Jagannath, S., & Barlogie, B. (1994). Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody. New England Journal of Medicine. https://doi.org/10.1056/nejm199403033300904
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.